Detailed View
ALNY - Alnylam Pharmaceuticals, Inc.
Latest filing: 2026-03-31 | Reporting: gaap
Market Cap
38,637,207,552
Adj EBIT (TTM)
1,113,814,000
Enterprise Value
36,926,428,552
Last Price
289.39
Earnings Yield
3.02%
Return on Capital
29.47%
Capital
3,780,072,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2026 | 1,167,175,000 | 268,636,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 1,097,033,000 | 131,718,000 |
| 2025-09-30 | 10-Q | 2025 | 1,249,026,000 | 367,982,000 |
| 2025-06-30 | 10-Q | 2025 | 773,689,000 | -16,199,000 |
| 2025-03-31 | 10-Q | 2025 | 594,189,000 | 18,077,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 593,166,000 | -105,159,000 |
| 2024-09-30 | 10-Q | 2024 | 500,919,000 | -76,905,000 |
| 2024-06-30 | 10-Q | 2024 | 659,825,000 | 48,614,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.